New drug duo aims to outperform standard chemo in aggressive breast cancer
NCT ID NCT07178730
Summary
This large trial aims to find better ways to control early-stage triple-negative breast cancer, an aggressive form of the disease. It will test if a new combination of two drugs (sacituzumab govitecan and pembrolizumab) works better than standard chemotherapy for patients who still have cancer after initial treatment. The study also explores if some patients can safely receive shorter treatment if they respond very well early on.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.